Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial Full Text
BMC Cancer, 05/24/2012
Fujita S et al. – Treatment customization based on epidermal growth factor receptor (EGFR) mutation status deserves consideration, particularly for elderly patients who often cannot receive second–line chemotherapy due to poor organ function or comorbidities.



